Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Thomas Modine Added: 3 weeks ago
EuroPCR25 - Findings from TRINITY trial show favourable outcomes with the LuX-Valve Plus TTVR system in high-risk patients with severe tricuspid regurgitation.We are joined by Prof Thomas Modine (CHU de Bordeaux, Bordeaux, FR) to discuss key findings from the TRINITY trial. This prospective, single-arm, multi-center study evaluated the LuX-Valve Plus transjugular tricuspid valve replacement… View more
Author(s): Nicolas M Van Mieghem Added: 7 months ago
TCT Conference 2024 - Safety and efficacy outcomes of transcatheter aortic valve replacement (TAVR) in addition to optimal heart failure therapy (OHFT) compared to OHFT alone in patients with heart failure and moderate aortic stenosis.Dr Nicolas M Van Mieghem (Erasmus University Medical Center, Rotterdam, NL) joins us onsite at TCT Conference to discuss the findings from TAVR UNLOAD (NCT02661451)… View more
Author(s): , Start date: Aug 06, 2025
Mitral and tricuspid regurgitation remain under-recognised and undertreated despite their significant impact on symptoms, quality of life, and outcomes. In this expert-led webinar, Suzanne V. Arnold, MD (Saint Luke’s Health System, Kansas City, US) offers practical guidance on recognising heart valve disease early, navigating referral pathways, and integrating patient-centred data into everyday… View more
Author(s): Didier Tchétché Added: 7 months ago
TCT Conference 2024 - Safety and efficacy outcomes of transcatheter aortic valve replacement (TAVR) compared to surgical aortic valve replacement (SAVR) in female patients with severe aortic stenosis.Dr Didier Tchétché (Clinique Pasteur, FR) joins us onsite at TCT Conference to discuss the pooled findings from the RHEIA (NCT04160130) and PARTNER 3 (NCT02675114) trials.RHEIA and PARTNER 3 are… View more